- 作者：Gwendolyn H.M.J. Griffioen ; Frank J. Lagerwaard ; Cornelis J.A. Haasbeek ; Egbert F. Smit ; Ben J. Slotman ; Suresh Senan
- 关键词：Multiple primary lung cancers ; Stereotactic ablative radiotherapy ; Lung cancer ; Survival
- 刊名：Radiotherapy and Oncology
- 出版年：2013
- 出版时间：June, 2013
- 年：2013
- 卷：107
- 期：3
- 页码：403-408
- 全文大小：744 K
Background and purpose
Multiple primary lung cancers (MPLC) are not an uncommon presentation. Current guidelines recommend a curative approach when early-stage MPLC is diagnosed as favorable outcomes have been reported after surgery. We studied outcomes following stereotactic ablative radiotherapy (SABR).Materials and methods
Following review of imaging and pathology at a multi-disciplinary tumor board, a total of 62 patients were referred for SABR with a diagnosis of synchronous MPLC. SABR was performed for both lesions in 56 patients, while another 6 underwent SABR for only one lesion and surgery for the other lesion. A total dose of 54-60 Gy was delivered in 3-8 fractions.
Results
Median follow-up was 44 months (95 % CI: 29-59). Overall survival of all patients was 31 months (95 % CI: 17-44), with an actuarial 2-year survival of 56 % . No grade 4 or 5 post-SABR toxicity was observed. Local control rates calculated per lesion, were 84 % at 2 years, and 78 % at 3 years. The two-year actuarial regional control rate was 87 % .
Conclusions
SABR for synchronous MPLC achieves a lesion control rate of 84 % after 2 years, with limited toxicity. SABR should be considered when patients with lung cancer present with a synchronous second lesion and no nodal involvement.